SELLAS Life Sciences Group Inc sell quelbe60
Start price
14.12.20
/
50%
€6.90
Target price
-
Performance (%)
-20.46%
End price
14.12.20
€5.49
Summary
This prediction ended on 14.12.20 with a price of €5.49. The price of SELLAS Life Sciences Group Inc decreased from the start of the prediction. Compared to the start price this resulted in a performance of -20.46%. quelbe60 has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | -5.028% | -5.028% | 10.390% | -80.571% |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
Comments by quelbe60 for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Sell SELLAS Life Sciences Group Inc
In the thread Trading SELLAS Life Sciences Group Inc
Stopped prediction by quelbe60 for SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€1.59
24.02.23
24.02.23
-
24.02.24
24.02.24
-4.83%
04.03.23
04.03.23
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€2.15
15.11.22
15.11.22
-
15.11.23
15.11.23
-26.97%
24.02.23
24.02.23
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€6.57
10.12.20
10.12.20
€5.00
0.52%
14.12.20
14.12.20